Cogent Biosciences Gains FDA Acceptance for Bezuclastinibm
WALTHAM, Mass. and BOULDER, Colo. — September 15, 2026 Cogent Biosciences, Inc. announced that the U.S. Food and Drug...
Arrowhead Pharmaceuticals
Advertisement
Vertex Partners With Lindsey Vonn to Highlight JOURNAVX
BOSTON — September 15, 2026 Vertex Pharmaceuticals Incorporated announced a partnership with world champion skier Lindsey Vonn to raise...
Arrowhead Advances ARO-DIMER-PA in Mixed Hyperlipidemia
PASADENA, Calif. — September 15, 2026 Arrowhead Pharmaceuticals, Inc. announced interim topline clinical data from the Phase 1/2a ARODIMER-PA-1001...
Arrowhead Reports Phase 3 Plozasiran Data Reducing Pancreatitis
Pasadena, Calif. – August 30, 2026 Arrowhead Pharmaceuticals presented detailed Phase 3 SHASTA-3 and SHASTA-4 data showing that plozasiran...
Arrowhead Expands REDEMPLO Access for FCS in Germany
PASADENA, Calif., August 17, 2026 Arrowhead Pharmaceuticals, Inc. announced that people living with familial chylomicronaemia syndrome (FCS) in Germany...
Advertisements
Arrowhead Pharmaceuticals Reports Positive Phase 3 Plozasiran Results
PASADENA, Calif., July 22, 2026 Arrowhead Pharmaceuticals announced positive topline results from its pivotal Phase 3 SHASTA-3 and SHASTA-4...
Arrowhead Pharmaceuticals and Madrigal Announce MASH Deal
PASADENA, Calif., United States – May 5, 2026 Arrowhead Pharmaceuticals Inc. has entered into an exclusive global licensing agreement...
Arrowhead Gains CHMP Nod for REDEMPLO in Rare Disease
Pasadena, California | April 24, 2026 Arrowhead Pharmaceuticals has achieved a major regulatory milestone as the Committee for Medicinal...
Arrowhead Pharma and Novartis Advance RNAi Therapy for Parkinson’s
Pasadena, CA – October 21, 2025 – Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has officially completed its global licensing and...
Advertisement
